For research and educational purposes only. Not intended for human consumption.
GLP1-S
Extensively Studied- •STEP UP 7.2mg trial: 21% weight loss
- •Type 1 diabetes trial success
- •2024 CV risk reduction FDA approval
- •MASH indication under review
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
What is GLP1-S?
GLP1-S is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes (GLP1-S), chronic weight management (GLP1-S), and cardiovascular risk reduction. The STEP UP trial (2025) demonstrates higher doses (7.2mg) achieve 21% mean weight loss vs 15.6% for 2.4mg, with over 90% achieving ≥5% loss and one-third losing ≥25% body weight.
Key Benefits
FDA-approved treatment with STEP UP 2025 data showing up to 21% weight loss at 7.2mg doses. Convenient once-weekly dosing with proven cardiovascular benefits (SELECT trial: 20% MACE reduction), newly approved for MASH (metabolic dysfunction-associated steatohepatitis), and comprehensive safety data from 17,000+ clinical trial participants.
Mechanism of Action
Subcutaneous glp1-s mimics native GLP-1, binding to GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing with sustained receptor activation.
Molecular Information
Pharmacokinetics
Research Indications
Clinically Significant Weight Reduction
FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.
Appetite and Craving Control
Reduces hunger and food cravings through central nervous system GLP-1 receptor activation.
Sustained Weight Maintenance
Long-term studies show maintained weight loss with continued treatment over 2+ years.
Research Protocols
Disclaimer: GLP1-S is an FDA-approved medication. These protocols reflect clinical trial guidelines. Always consult a healthcare provider before use. Dose titration is required to minimize side effects.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight Loss Initiation | 0.25mg | Weekly x 4 weeks, then increase | Subcutaneous |
| Weight Loss Maintenance | 2.4mg | Weekly (after 16-week titration) | Subcutaneous |
| Diabetes Management | 0.5-1mg | Weekly | Subcutaneous |
| Cardiovascular Protection | 0.5-1mg | Weekly | Subcutaneous |
| Tolerability-Based | 0.25-2.4mg | Weekly (individualized) | Subcutaneous |
Timing: Inject on the same day each week at any time. If you miss a dose and it's within 5 days, take it as soon as remembered. If more than 5 days, skip and resume regular schedule.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
If using pre-filled pen, attach new needle and prime according to instructions
If using vial, draw prescribed dose with appropriate syringe
Clean injection site with alcohol swab and let dry
Inject subcutaneously at 90-degree angle (45-degree if lean)
Hold for 6 seconds after injection to ensure full dose delivery
Dispose of needle safely and rotate injection sites weekly
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
FDA-Approved Branded Products
Use only GLP1-S (diabetes) or GLP1-S (weight loss) from licensed pharmacies.
Proper Storage Verification
Check that medication was properly refrigerated and not expired.
Clear Solution in Pen/Vial
Solution should be clear and colorless to slightly yellow.
Compounded Versions
FDA warns about untested compounded glp1-s - use only approved products.
Cloudy or Discolored Solution
Do not use if solution is cloudy, has particles, or unusual color.
Non-Pharmacy Sources
Avoid online sources not verified as licensed pharmacies.
What to Expect
- •Week 1-4: Mild appetite reduction, possible nausea during initial dose
- •Month 2-3: Noticeable weight loss (5-10% typical), improved satiety
- •Month 4-6: Continued weight loss (10-15% common), stable glucose levels
- •Month 6+: Weight loss plateau possible, focus on maintenance
- •Diabetes benefits: Blood sugar improvements within 1-2 weeks
- •Long-term: Sustained benefits with continued use
Side Effects & Safety
Side Effects
- •FDA-approved medication with extensive safety data
- •Start low and titrate slowly to minimize GI side effects
- •Most common side effects: nausea, diarrhea, vomiting, constipation
- •Contraindicated in personal/family history of medullary thyroid cancer or MEN 2
- •Monitor for signs of pancreatitis (severe abdominal pain)
- •Not recommended in pregnancy or breastfeeding
When to Stop
- •Severe or persistent nausea/vomiting
- •Signs of pancreatitis (severe abdominal pain)
- •Allergic reactions
- •Severe hypoglycemia
- •Changes in vision
- •Kidney problems
- •Consult healthcare provider immediately
References
5 StudiesSTEP UP Trial - 7.2mg Dose (2025)
Phase 3b | 512 adults with obesity | 72 weeks | 21% weight loss at 7.2mg vs 15.6% at 2.4mg vs 2.5% placebo
Landmark trial showing higher 7.2mg dose achieves 21% mean weight loss, with >90% achieving ≥5% loss and one-third losing ≥25% body weight. Over 50% reached ≥20% loss.
View StudySELECT Cardiovascular Outcomes
17,604 participants | 2.4mg weekly | 5 years | 20% CV risk reduction
Major cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events in overweight/obese adults with established CVD, earning 2024 FDA approval for CV risk reduction.
Type 1 Diabetes Trial (2025)
36 adults with BMI ≥30 | 26 weeks | Insulin pump users | ~10% weight loss (20 lbs average)
First trial in Type 1 diabetes showing weekly glp1-s enables ~10% average weight loss with better glycemic control - 36% met composite targets vs 0% placebo, no severe complications.
Quick Start Guide
Research Disclaimer
GLP1-S is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving GLP1-S must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of GLP1-S for any purpose. Consult qualified professionals for any research applications.